Evidence map›Paper›PMID 40892509›Full record

ReviewThe Journal of clinical investigation2025

Maladaptive trained immunity in viral infections.

Dmitri Sviridov, Mihai G Netea, Michael I Bukrinsky

Abstract readReview
In one paragraph

Review in The Journal of clinical investigation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Review
  2. Article
  3. Immune development in early life.Nature immunology · 2026
    Review
  4. Review
  5. Article
  6. Article
  7. Training the Lung, Taming the NETs.Frontiers in cellular and infection microbiology · 2026
    Article
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Dmitri SviridovBaker Heart and Diabetes Institute, Melbourne, Victoria, Australia.
Mihai G NeteaDepartment of Internal Medicine and Radboud Center for Infectious Diseases, Radboud University Medical Center, Nijmegen, Netherlands.
Michael I BukrinskyDepartment of Microbiology, Immunology, and Tropical Medicine, The George Washington University School of Medicine and Health Sciences, Washington, DC, USA.

Funding

SWG 2: Cure Research Scientific Working GroupP30AI117970 · NIAID · GEORGE WASHINGTON UNIVERSITY · PI Italo Mocchetti · 2015 to 2026
$29.6M
Supplement to R01 NS124477R01NS124477 · NINDS · GEORGE WASHINGTON UNIVERSITY · PI BUKRINSKY, MICHAEL ILYA, TYOR, WILLIAM R · 2021 to 2025
$3.6M
Epigenetic Reprogramming in HIV-Associated Cardio-Vascular DiseaseR01HL140977 · NHLBI · GEORGE WASHINGTON UNIVERSITY · PI BUKRINSKY, MICHAEL ILYA, FITZGERALD, MICHAEL LEO · 2018 to 2021
$3.1M
Lipid raft therapy – a novel therapeutic approach for HIV-associated cardiometabolic co-morbiditiesR01HL158305 · NHLBI · GEORGE WASHINGTON UNIVERSITY · PI BUKRINSKY, MICHAEL ILYA, SVIRIDOV, DMITRI · 2021 to 2024
$2.6M
Epigenetic mechanisms of HAND pathogenesisR21NS137986 · NINDS · GEORGE WASHINGTON UNIVERSITY · PI MICHAEL Ilya BUKRINSKY, Dmitri Sviridov · 2024 to 2026
$454k
Trained immunity induced by Nef-containing extracellular vesiclesR21AI172028 · NIAID · GEORGE WASHINGTON UNIVERSITY · PI BUKRINSKY, MICHAEL ILYA · 2022 to 2023
$444k
NHLBI NIH HHS R01 HL140977NHLBI NIH HHS R01 HL158305NIAID NIH HHS P30 AI117970NIAID NIH HHS R21 AI172028NINDS NIH HHS R01 NS124477NINDS NIH HHS R21 NS137986
6 · The paper itself

Abstract

Trained immunity (TRIM) is a form of long-lasting functional reprogramming of innate immune cells and their progenitors that enhances responsiveness to subsequent stimuli. Although first characterized in myeloid cells, TRIM was recently extended to nonmyeloid cell types, including endothelial and glial cells, which also exhibit stimulus-driven, memory-like behavior. While initially recognized as a protective mechanism, particularly in the context of vaccines and acute infections, TRIM can also become maladaptive, promoting chronic inflammation, immune dysfunction, and disease. This Review focuses on virus-induced TRIM while also addressing microbial, metabolic, and endogenous inducers. We examine key ligands and receptors that initiate TRIM and dissect the associated signaling and epigenetic pathways. Importantly, we argue that maladaptive TRIM arises not from a specific ligand, receptor, or molecular event, but from contextual factors such as stimulus persistence, dose, tissue microenvironment, and preexisting inflammation. The nature of the secondary challenge also shapes whether a trained response is adaptive or maladaptive. We further discuss TRIM induction in the bone marrow, involvement of both myeloid and nonmyeloid cells, and the role of lipid rafts in sustaining TRIM. We review maladaptive TRIM's potential contribution to systemic diseases, such as atherosclerosis, diabetes, sepsis, cancer, and autoimmunity, along with its influence on viral vaccine responses. Finally, we outline potential strategies to redirect maladaptive TRIM and propose key outstanding questions for future research.

Indexed as

Immunity, InnateImmunologic MemoryVirus DiseasesAnimalsEpigenesis, GeneticHumansSignal TransductionTrained Immunity

Identifiers

PMID40892509
PMCPMC12404746

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.